At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
TRVN Trevena
Not Yet Opened 05-28 16:00:00 EDT
0.3850
-0.0150
-3.75%
盘后0.4094
+0.0244+6.34%
16:30 EDT
High0.4100
Low0.3800
Vol70.01K
Open0.4100
D1 Closing0.4000
Amplitude7.50%
Mkt Cap7.05M
Tradable Cap6.38M
Total Shares18.32M
T/O27.80K
T/O Rate0.42%
Tradable Shares16.56M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
North American Morning Briefing: Stocks Drift as Metals Hover Around Records
BRIEF-Trevena- Got Letter From Nasdaq Hearings Panel Granting Extension Until August 28, To Regain Compliance With Nasdaq Continued Listing Requirements
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.